[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612082":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":149,"collaborators":29,"id":152,"slug":29,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":29,"eligibilityCriteria":157,"healthyVolunteers":153,"sex":158,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":29,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":115,"whyStopped":29,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"neoadjuvant therapy followed by surgery and (C)RT group","EXPERIMENTAL","Patients initially receive immunotherapy with Finolizumab and chemotherapy with albumin-bound paclitaxel and cisplatin. Patients with response of complete reaction (CR)\u002Fpartial reaction (PR)≥50% after neoadjuvant chemotherapy then receive surgery, followed by postoperative radiotherapy or chemoradiotherapy.",[13,14,15,16],"Drug: Finolizumab","Drug: Albumin-Bound Paclitaxel \u002Fnab-Paclitaxel","Drug: Cisplatin","Procedure: Surgery with postoperative radiotherapy or chemoradiotherapy.",{"label":18,"type":19,"description":20,"interventionNames":21},"neoadjuvant therapy followed by CCRT group","ACTIVE_COMPARATOR","Patients initially receive immunotherapy with Finolizumab and chemotherapy with albumin-bound paclitaxel and cisplatin. Patients with response of complete reaction (CR)\u002Fpartial reaction (PR)≥50% after neoadjuvant chemotherapy then receive definitive radiotherapy with concurrent cisplatin-based chemotherapy.",[13,14,15,22],"Radiation: Definitive radiotherapy",[24,30,34,38,43],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Finolizumab","200mg every 3 weeks (q3w) for 2 cycles.",[18,9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Albumin-Bound Paclitaxel \u002Fnab-Paclitaxel","260mg\u002Fm², day 1, every 3 weeks (q3w) for 2 cycles.",[18,9],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Cisplatin","25mg\u002Fm², days 1-3, every 3 weeks (q3w) for 2 cycles.",[18,9],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":29},"RADIATION","Definitive radiotherapy","Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg\u002Fm², days 1-3, every 3 weeks)",[18],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":29},"PROCEDURE","Surgery with postoperative radiotherapy or chemoradiotherapy.","surgery with postoperative radiotherapy or chemoradiotherapy.",[9],[49],{"name":50,"affiliation":51,"role":52},"Ming Zhang, PhD","Eye & ENT Hospital, Fudan University","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":29,"email":58},"Chiyao Hsueh","CONTACT","021-64377134","hsuehchiyao@gmail.com",[60,77,91,104,114,126,136],{"facility":61,"status":62,"city":63,"state":64,"zip":29,"country":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Harbin Medical University Cancer Hospital","NOT_YET_RECRUITING","Harbin","Heilongjiang","China",{"type":67,"coordinates":68},"Point",[69,70],126.65,45.75,{"lat":70,"lon":69},[73],{"name":74,"role":56,"phone":75,"phoneExt":29,"email":76},"Susheng Miao, PhD","8613796620079","drmiaosusheng@126.com",{"facility":78,"status":62,"city":79,"state":80,"zip":29,"country":65,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Shandong Provincial ENT Hospital","Jinan","Shandong",{"type":67,"coordinates":82},[83,84],116.99722,36.66833,{"lat":84,"lon":83},[87],{"name":88,"role":56,"phone":89,"phoneExt":29,"email":90},"Zhenghua Lv, PhD","8615168889970","entlvzhenghua@163.com",{"facility":92,"status":62,"city":93,"state":29,"zip":29,"country":65,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Beijing Tongren Hospital, Capital Medical University","Beijing",{"type":67,"coordinates":95},[96,97],116.39723,39.9075,{"lat":97,"lon":96},[100],{"name":101,"role":56,"phone":102,"phoneExt":29,"email":103},"Qi Zhong, PhD","8613520298736","zhongqi_ent@126.com",{"facility":105,"status":62,"city":93,"state":29,"zip":29,"country":65,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"Cancer Hospital Chinese Academy of Medical Sciences",{"type":67,"coordinates":107},[96,97],{"lat":97,"lon":96},[110],{"name":111,"role":56,"phone":112,"phoneExt":29,"email":113},"Changming An, PhD","8613811381160","mran1979@163.com",{"facility":51,"status":115,"city":116,"state":29,"zip":29,"country":65,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"RECRUITING","Shanghai",{"type":67,"coordinates":118},[119,120],121.45806,31.22222,{"lat":120,"lon":119},[123],{"name":50,"role":56,"phone":124,"phoneExt":29,"email":125},"8621-64377151","zmzlm@163.com",{"facility":127,"status":62,"city":116,"state":29,"zip":29,"country":65,"cosmosGeoPoint":128,"geoPoint":130,"contacts":131},"Zhongshan Hospital of Fudan University",{"type":67,"coordinates":129},[119,120],{"lat":120,"lon":119},[132],{"name":133,"role":56,"phone":134,"phoneExt":29,"email":135},"Xinsheng Huang, PhD","8613681791739","huang.xinsheng@zs-hospital.sh.cn",{"facility":137,"status":62,"city":138,"state":29,"zip":29,"country":65,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Tianjin Medical University Cancer Institute & Hospital","Tianjin",{"type":67,"coordinates":140},[141,142],117.17667,39.14222,{"lat":142,"lon":141},[145],{"name":146,"role":56,"phone":147,"phoneExt":29,"email":148},"Xuan Zhou, PhD","8618622682591","xuanzhou@tmu.edu.cn",{"type":52,"investigatorFullName":150,"investigatorTitle":151,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Ming Zhang","Principal Investigator","100612082",false,"NCT07248956","Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma","Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Willingness to provide written informed consent;\n2. Age ≥18 and ≤75 years;\n3. Treatment-naïve for malignant disease;\n4. Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ;\n5. ECOG performance status 0-2.\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding status;\n2. Hypersensitivity to sintilimab, nab-paclitaxel, or their formulation components;\n3. Poorly controlled cardiovascular conditions or other diseases;\n4. Active or documented history of autoimmune diseases requiring systemic treatment;\n5. Synchronous or metachronous malignancies;\n6. Other conditions deemed ineligible for the study by investigators.","ALL","18 Years","75 Years",{"count":162,"type":163},116,"ESTIMATED","INTERVENTIONAL",[166],"PHASE2","This is a multi-center, randomized controlled, prospective clinical study.",[169],"Hypopharyngeal Carcinoma",[171,172,173],"PD-1 inhibitor","neoadjuvant therapy","locally advanced","2025-12-22",{"date":176,"type":177},"2025-12-23","ACTUAL",{"date":174,"type":177},{"date":180,"type":163},"2029-12-30",{"name":5,"class":6},7]